Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 525%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.53 per share when it actually produced a loss of $0.50, delivering a surprise of 5.66%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Esperion Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $137.74 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 159.32%. This compares to year-ago revenues of $24.33 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Esperion
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®GlobeNewswire
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.MarketBeat
- Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 5/7/24 - Beat
ESPR
Sec Filings
- 5/17/24 - Form 144
- 5/8/24 - Form 8-K
- 5/7/24 - Form 10-Q
- ESPR's page on the SEC website